Pilot Feasibility and Efficacy Trial of a Novel Reversible LSD1 Inhibitor SP-2577 (Seclidemstat) Plus Pembrolizumab in Select SWI/SNF-mutant Gynecologic Cancers

Open-label study of SF-2577 plus pembrolizumab in advanced, recurrent small cell ovarian cancer as well as select additional ovarian and endometrial cancers within the SWI/SNF pathway.

Start Date31 Dec 2021

Sponsor / Collaborator

Scottsdale Healthcare Corp.

[+2]

NCT05226507 / RecruitingPhase 1

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

Start Date31 Dec 2021

Sponsor / Collaborator

Nuvectis Pharma, Inc.

[+2]

CTR20201170 / TerminatedPhase 1/2

一项MAK683用于晚期恶性肿瘤成人患者的I/II期、多中心、开放性研究

[Translation] A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients with Advanced Malignancies

本项I/II期研究目的在晚期恶性肿瘤患者中（非霍奇金淋巴瘤、鼻咽癌或目前无更多有效标准治疗方法的其他晚期实体瘤）确定MAK683的最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）并评估安全性、抗肿瘤活性和药代动力学（PK）特征

[Translation]

The purpose of this Phase I/II study is to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of MAK683 in patients with advanced malignancies (non-Hodgkin's lymphoma, nasopharyngeal carcinoma, or other advanced solid tumors for which no more effective standard treatments are currently available) and to evaluate safety, antitumor activity, and pharmacokinetic (PK) characteristics.

Start Date30 Sep 2021

Sponsor / Collaborator

China Novartis Institutes for BioMedical Research Co., Ltd.

[+1]

100 Clinical Results associated with Clear cell neoplasm of ovary

100 Translational Medicine associated with Clear cell neoplasm of ovary

0 Patents (Medical) associated with Clear cell neoplasm of ovary

Literatures (Medical) associated with Clear cell neoplasm of ovary

01 May 2024·The Journal of Steroid Biochemistry and Molecular Biology

The effect of androgens on the risk of endometriosis sub-phenotypes and ovarian neoplasms: A Mendelian randomization study

Article

Author: Rizner, Tea Lanisnik ; Gjorgoska, Marija

Endometriosis is a complex gynecological pathology with a broad spectrum of symptoms, affecting around 10% of reproductive-aged women. Ovarian cancer (OC) is a heterogeneous disease for which we lack effective diagnostic and therapeutic strategies. The etiology and pathogenesis of both diseases remain ambiguous. Androgens in endometriosis could have a distinct role beyond serving as estrogen sources, whereas in the case of serous OC could be important in the formation of precursor lesions which ultimately lead to tumor formation. Here we performed two-sample Mendelian randomization (MR) analysis to examine the causal relationship between the androgen precursor - dehydroepiandrosterone sulphate (DHEAS), bioactive androgen - testosterone (T), androgen metabolite - androsterone sulphate, steroid hormone binding globulin (SHBG) and albumin and the risk of endometrioses of various sub-phenotypes and ovarian neoplasms across the benign-borderline-malignant spectrum. Stringent quality control procedures were followed to select eligible instrumental variables that were strongly associated with the selected exposures, sensitivity analyses were performed to assess the heterogeneities, horizontal pleiotropy, and stabilities of SNPs in endometriosis and ovarian neoplasms. We discovered an inverse association between genetically predicted levels of all androgens and risk of endometriosis, the same trend was most evident in the ovarian sub-phenotype. Total T levels were also inversely associated with peritoneal sub-phenotype of endometriosis. Likewise, T was causally associated with decreased risk of clear-cell OC, an endometriosis-associated OC subtype, and with malignant serous OC of both low- and high-grade, but with higher risk of their counterpart of low malignant potential. These findings support further investigation of androgen's action at a molecular level in ovary-associated endometriotic lesions, clear cell ovarian tumors and serous precursor lesions.

01 Jan 2022·International Journal of Gynecological PathologyQ4 · MEDICINE

Ovarian Clear Cell Tumors Associated With Seromucinous Borderline Tumor: A Case Series

Q4 · MEDICINE

Article

Author: McCluggage, W. Glenn ; Vroobel, Katherine M. ; W Glenn McCluggage

Ovarian seromucinous borderline tumors (SMBT) and clear cell tumors are both closely associated with endometriosis and share, in a proportion of cases, a molecular pathway involving ARID1A mutations, but they have been rarely described in association. We report a case series of 4 clear cell tumors (3 carcinomas, 1 borderline adenofibroma) coexisting in the same ovary with SMBT. In all cases, the SMBT was the predominant component and we highlight that adequate sampling of these tumors is important to detect small clear cell carcinomas, thus potentially altering the treatment and prognosis.

01 Sep 2019·International Journal of Gynecological PathologyQ4 · MEDICINE

Next-generation Sequencing of an Ovarian Spindle Cell Tumor Identified an Ovarian Low-grade Endometrial Stromal Sarcoma: A Rare Entity

Q4 · MEDICINE

Article

Author: Liu, Jingjing ; Ho, Jungyoon ; Choi, Youn Jin ; Hur, Soo Young ; Lee, Ahwon ; Park, Jong Sup ; Yoo, Jigeun

Ovarian spindle cell tumors comprise a heterogeneous group of ovarian neoplasms from benign to malignant. Since this morphologic finding describes a broad category of ovarian neoplasms, it is not easy to determine an accurate diagnosis. Low-grade endometrial stromal sarcoma (LG-ESS) is a rare gynecological malignancy that presents with spindle cell lesions. To identify ovarian LG-ESS, we performed whole-exome sequencing and transcriptome sequencing of a spindle cell tumor. The tumor harbored JAZF1-SUZ12, a well-known gene fusion commonly found in uterine LG-ESS. Moreover, 28 non-silent somatic mutations (13 frameshift, 12 missense, 2 nonsense and 1 splicing mutations) with five cancer-related genes (ACSL3, ATM, DST, HGF and PKHD1) were detected. Our results indicate that next-generation sequencing combined with conventional immunohistochemical analysis may be a better strategy than conventional analysis alone to identify ovarian LG-ESS with spindle cell lesions. Moreover, our data suggest that ovarian LG-ESS can harbor genetic characteristics similar to those of uterine LG-ESS.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Clear cell neoplasm of ovary

Basic Info

Related

Analysis